Chronic administration of melatonin reduces cerebral injury biomarkers in SAMP8

Gutierrez-Cuesta, Javier; Sureda, Francesc X.; Romeu, Marta; Canudas, Anna M.; Caballero, Beatriz; Coto-Montes, Ana; Camins, Antoni; Pallas, Merce


Certain effects of melatonin on senescence were investigated. The experimental model used was 10-month-old senescence-accelerated mouse prone 8 (SAMP8). The mice in the experiment were administered melatonin (10 mg/kg) from the age of 1 month. Results showed that chronic administration of melatonin decreased cell loss in the cerebral cortex and reduced oxidative damage in protein and lipids. There are several studies suggesting that the activation of the cdk5/p35 pathway at its cleavage to cdk5/p25 may play a role in hyperphosphorylation of tau during aging and neurodegenerative diseases. Melatonin not only reduced the cerebral aging disturbances, but also prevented tau hyperphosphorylation present in the experimental model used in this study. Melatonin reduced cdk5 expression, as well as the cleavage of p35 to p25. The other tau kinase studied, GSK3 beta, showed a reduction in this activity in comparison with SAMP8 nontreated SAMP8. These data indicate that melatonin possesses neuroprotective properties against cerebral damage gated to senescence. Moreover, these data suggest that the cdk5/GSK beta signaling cascade has a potential role as a target for neurodegenerative diseases related to aging.

Más información

Título según WOS: ID WOS:000245612600010 Not found in local WOS DB
Volumen: 42
Número: 4
Editorial: Wiley
Fecha de publicación: 2007
Página de inicio: 394
Página final: 402


Notas: ISI